Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.

NCT06492122 is registered in ClinicalTrials.gov with Full-Life Technologies UK Limited as lead sponsor.

NCT NCT06492122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06492122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.
Lead sponsor
Full-Life Technologies UK Limited
Phase
Phase 1
Overall status
Recruiting
Start date
August 30, 2024
Completion date
September 30, 2027
Enrollment
50 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer